Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes

NCT01605773 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

DRUG: repaglinide
DRUG: glyburide

Sponsor

Novo Nordisk A/S